WuXi AppTec Sues U.S. Department of Defense; Mabwell's First-in-Class LILRB4/CD3 Bispecific Antibody Receives FDA Clinical Clearance
WuXi AppTec
New Drug R&D and Production Service Provider
Mabwell
Innovative Biopharmaceutical Company
Simcere
Innovative Drug Developer
Neuracle
Developer and Manufacturer of Brain-Computer Interface Systems and Related Equipment
Amino Observation - Original Production by the Innovative Drug Group
Author | Huang Kai
WuXi AppTec Takes the Initiative!
On June 12, WuXi AppTec announced that it had filed a lawsuit against the U.S. Department of Defense in the U.S. District Court for the District of Columbia on June 11 (U.S. time) regarding the Department’s erroneous inclusion of WuXi AppTec in the updated list of “Chinese Military Companies” (CMCs) identified under Section 1260H.
Mabwell’s FIC Bispecific Antibody Receives FDA Clinical Trial Approval.
On June 12, Mabwell announced that its independently developed innovative bispecific antibody drug 6MW5311, a T-cell engager (TCE) targeting LILRB4/CD3, has received FDA authorization to initiate clinical trials for hematologic malignancies. 6MW5311 is the first innovative LILRB4/CD3-targeting TCE drug globally to be approved for clinical trials.
What other hot topics in the domestic and international pharmaceutical markets are worth paying attention to in the past day? Let Amin Jun take you to explore.
/ 01 /
Market Flash
1) WuXi AppTec Sues the U.S. Department of Defense
On June 12, WuXi AppTec announced that it had filed a lawsuit against the U.S. Department of Defense in the U.S. District Court for the District of Columbia on June 11 (U.S. time) regarding the Department’s erroneous inclusion of WuXi AppTec in the updated list of “Chinese Military Companies” (CMCs) identified under Section 1260H.
2) Stanford University School of Medicine and Simcere Reach Research Collaboration Agreement
On June 12, Simcere announced that it had recently entered into a collaborative research agreement with Stanford University School of Medicine to jointly advance an exploratory study in the field of respiratory diseases, aiming to develop innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). Under the agreement, Simcere will fund the exploratory research on this first-in-class novel molecule, secure licensing rights upon successful development, and obtain 100% global commercial rights to the resulting product.
/ 02 /
Capital Information
1) Neuracle Applies for Listing on the STAR Market
On June 11, according to the STAR Market Observer, Neuracle’s IPO application was accepted.
/ 03 /
Pharmaceutical Dynamics
1) Mabwell’s LILRB4/CD3 Bispecific Antibody Receives FDA Clinical Trial Authorization
On June 12, Mabwell announced that its independently developed innovative bispecific antibody drug 6MW5311, a T-cell engager (TCE) targeting LILRB4/CD3, has received FDA authorization to initiate clinical trials for hematologic malignancies. 6MW5311 is the first innovative LILRB4/CD3-targeting TCE drug globally to be approved for clinical trials.
/ 04 /
Overseas Pharmaceutical News
1) Takeda’s TYK2 Inhibitor Achieves Success Again in Head-to-Head Phase III Study
On June 11, Takeda announced that the Phase III study of Zasocitinib (TAK-279) versus deucravacitinib for the treatment of plaque psoriasis (LATITUDE Atlas, TAK-279-PsO-3004) met its primary endpoint.
P.S.: Welcome to scan the QR code below to add Aminojun on WeChat for communication.
